Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Public ClinicalTrials.gov record NCT04191616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)
Study identification
- NCT ID
- NCT04191616
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib Drug
- Dexamethasone Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2020
- Primary completion
- Nov 29, 2022
- Completion
- Sep 30, 2024
- Last update posted
- Sep 3, 2025
2020 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Rocky Mountain Cancer Centers Denver Midtown | Denver | Colorado | 80218 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Affiliated Oncologists, LLC | Chicago Ridge | Illinois | 60415 | — |
| Minnesota Oncology Hematology PA | Saint Paul | Minnesota | 55102 | — |
| Oncology Hematology Care Incorporated | Cincinnati | Ohio | 45236 | — |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | — |
| United States Oncology Regulatory Affairs Corporate Office | Austin | Texas | 78705 | — |
| US Oncology Research Investigational Products Center | Austin | Texas | 78705 | — |
| Baylor Charles A Sammons Cancer Center at Dallas | Dallas | Texas | 75246 | — |
| Texas Oncology, Fort Worth | Fort Worth | Texas | 76104 | — |
| Texas Oncology- Tyler | Tyler | Texas | 75702 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04191616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04191616 live on ClinicalTrials.gov.